140 related articles for article (PubMed ID: 11097092)
1. Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma.
Bermont L; Algros MP; Baron MH; Adessi GL
Breast Cancer Res Treat; 2000 Sep; 63(2):163-9. PubMed ID: 11097092
[TBL] [Abstract][Full Text] [Related]
2. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM
Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395
[TBL] [Abstract][Full Text] [Related]
3. p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification.
Dalifard I; Daver A; Goussard J; Lorimier G; Gosse-Brun S; Lortholary A; Larra F
Int J Mol Med; 1998 May; 1(5):855-61. PubMed ID: 9852307
[TBL] [Abstract][Full Text] [Related]
4. [Molecular protocol for HER2/neu analysis in breast carcinoma].
Artufel MV; Valero AC; Lladó RR; Sagalés NE; Llorca MC; Carazo AM; Cardó CC; Torrus XP
Clin Transl Oncol; 2005 Dec; 7(11):504-11. PubMed ID: 16373062
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors.
Valerón PF; Chirino R; Vega V; Falcón O; Rivero JF; Torres S; León L; Fernández L; Pestano J; Díaz-Chico B; Díaz-Chico JC
Int J Cancer; 1997 Apr; 74(2):175-9. PubMed ID: 9133451
[TBL] [Abstract][Full Text] [Related]
6. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
Titi S
Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades.
Marsigliante S; Muscella A; Ciardo V; Barker S; Leo G; Baker V; Mottaghi A; Vinson GP; Storelli C
Cancer Lett; 1993 Dec; 75(3):195-206. PubMed ID: 7906196
[TBL] [Abstract][Full Text] [Related]
8. Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations.
Cuny M; Simony-Lafontaine J; Rouanet P; Grenier J; Valles H; Lavaill R; Louason G; Causse A; Lequeux N; Thierry C
Oncol Res; 1994; 6(4-5):169-76. PubMed ID: 7841539
[TBL] [Abstract][Full Text] [Related]
9. [Overexpression of c-erbB-2 gene product is associated with poor prognosis factors in breast carcinoma].
Cianga C; Cianga P; Cozma L; Diaconu C; Carasevici E
Rev Med Chir Soc Med Nat Iasi; 2003; 107(2):349-53. PubMed ID: 14755939
[TBL] [Abstract][Full Text] [Related]
10. c-erbB-2 amplification and overexpression in breast cancer: evaluation and comparison of Southern blot, slot blot, ELISA and immunohistochemistry.
Dawkins HJ; Robbins PD; Sarna M; Carrello S; Harvey JM; Sterrett GF
Pathology; 1993 Apr; 25(2):124-32. PubMed ID: 8103591
[TBL] [Abstract][Full Text] [Related]
11. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
13. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients.
Riou G; Mathieu MC; Barrois M; Le Bihan ML; Ahomadegbe JC; Bénard J; Lê MG
Int J Cancer; 2001 Jul; 95(4):266-70. PubMed ID: 11400121
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the quantitative measurement of the oncoprotein p185(Her-2/neu) in a group of patients with breast cancer and positive node involvement.
Bohn U; Aguiar J; Bilbao C; Murias A; Vega V; Chirino R; Díaz-Chico N; Díaz-Chico JC
Int J Cancer; 2002 Oct; 101(6):539-44. PubMed ID: 12237894
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer.
Shi D; He G; Cao S; Pan W; Zhang HZ; Yu D; Hung MC
Mol Carcinog; 1992; 5(3):213-8. PubMed ID: 1350198
[TBL] [Abstract][Full Text] [Related]
16. c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization.
Haapasalo H; Hyytinen E; Sallinen P; Helin H; Kallioniemi OP; Isola J
Br J Cancer; 1996 Mar; 73(5):620-3. PubMed ID: 8605096
[TBL] [Abstract][Full Text] [Related]
17. Immunometric assays of ras and c-erbB-2/neu overexpression in breast cancer: a pilot study.
Pelizzola D; Malagutti R; Giovannini G; Indelli M; Carcoforo P; Piffanelli A
Int J Biol Markers; 1999; 14(3):178-85. PubMed ID: 10569141
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
19. c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome.
Dati C; Muraca R; Tazartes O; Antoniotti S; Perroteau I; Giai M; Cortese P; Sismondi P; Saglio G; De Bortoli M
Int J Cancer; 1991 Apr; 47(6):833-8. PubMed ID: 1672666
[TBL] [Abstract][Full Text] [Related]
20. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.
Wang S; Saboorian MH; Frenkel E; Hynan L; Gokaslan ST; Ashfaq R
J Clin Pathol; 2000 May; 53(5):374-81. PubMed ID: 10889820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
